Calcimedica reports second quarter 2024 financial results and provides clinical & corporate updates

Positive topline data announced from carpo, phase 2b trial of auxora™ in acute pancreatitis (ap); additional data to be presented at a medical meeting later this year first patient enrolled in kourage, phase 2 trial of auxora™ in severe acute kidney injury (aki), with data expected in 2025 la jolla, calif. , aug. 12, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica or the company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended june 30, 2024.
CALC Ratings Summary
CALC Quant Ranking